Milnacipran
- Generic Name
- Milnacipran
- Brand Names
- Savella
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22N2O
- CAS Number
- 92623-85-3
- Unique Ingredient Identifier
- G56VK1HF36
- Background
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression . Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional ...
- Indication
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above .
...
- Associated Conditions
- Fibromyalgia
- Associated Therapies
- -
Effect of Milnacipran / Gabapentin in Fibromyalgia
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 75
- Registration Number
- NCT05384210
- Locations
- 🇪🇬
Mansoura University, Mansoura, DK, Egypt
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 80
- Registration Number
- NCT02783430
- Locations
- 🇫🇷
Chu Amiens Picardie, Amiens, France
🇫🇷Ch Calais, Calais, France
🇫🇷Maison Medicale Jean Xxiii - Lille, Lille, France
Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With Sciatica
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 150
- Registration Number
- NCT01914042
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Duke University
- Target Recruit Count
- 26
- Registration Number
- NCT01829243
- Locations
- 🇺🇸
Duke University Medical Center / Civitan Building, Durham, North Carolina, United States
Milnacipran for Lumbosacral Radicular Pain
- Conditions
- Interventions
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Duke University
- Target Recruit Count
- 13
- Registration Number
- NCT01777581
Prospective Study of the Influence of the Diffuse Noxious Inhibitory Controls of the Pain on the Efficacy of Milnacipran in Fibromyalgia Therapy
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Target Recruit Count
- 48
- Registration Number
- NCT01747044
- Locations
- 🇫🇷
CHU de Clermont-Ferrand, Clermont-Ferrand, France
Milnacipran for Chronic Pain in Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Dr. Norman Harden
- Target Recruit Count
- 46
- Registration Number
- NCT01510457
Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Spencer Dorn, MD, MPH
- Target Recruit Count
- 2
- Registration Number
- NCT01471379
- Locations
- 🇺🇸
UNC Center for Functional GI and Motility Disorders, Chapel Hill, North Carolina, United States
Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Banner Health
- Target Recruit Count
- 20
- Registration Number
- NCT01418651
- Locations
- 🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States
Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Timothy Smith
- Target Recruit Count
- 37
- Registration Number
- NCT01393522
- Locations
- 🇺🇸
Headache Wellness Center, Greensboro, North Carolina, United States
🇺🇸Mercy Health Research, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.